These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 33896328)

  • 1. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
    Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
    Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
    Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
    Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in Adult Acute Lymphoblastic Leukemia.
    Richard-Carpentier G; Kantarjian H; Jabbour E
    Curr Hematol Malig Rep; 2019 Apr; 14(2):106-118. PubMed ID: 30879177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibodies in acute lymphoblastic leukemia therapy.
    Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
    Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.
    Martino M; Alati C; Canale FA; Musuraca G; Martinelli G; Cerchione C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.
    Leahy AB; Elgarten CW; Grupp SA; Maude SL; Teachey DT
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):959-971. PubMed ID: 30111196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
    Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy.
    Aldoss I; Forman SJ
    Blood; 2020 Mar; 135(11):804-813. PubMed ID: 31899793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
    Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
    Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
    Kantarjian H; Jabbour E
    Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Frey NV; Luger SM
    Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome.
    Chen L; Xu B; Long X; Gu J; Lou Y; Wang D; Cao Y; Wang N; Li C; Wang G; Wang Y; Zhu L; Wang J; An H; Xiao M; Xiao Y; Zhou J
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma.
    DuVall AS; Wesevich A; Larson RA
    Curr Hematol Malig Rep; 2023 Dec; 18(6):217-225. PubMed ID: 37490229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed/refractory acute lymphoblastic leukemia.
    Paul S; Rausch CR; Nasnas PE; Kantarjian H; Jabbour EJ
    Clin Adv Hematol Oncol; 2019 Mar; 17(3):166-175. PubMed ID: 30969955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.
    Horvat TZ; Seddon AN; Ogunniyi A; King AC; Buie LW; Daley RJ
    Ann Pharmacother; 2018 Mar; 52(3):268-276. PubMed ID: 29025266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
    Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
    Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
    J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.